Literature DB >> 2467377

Identification of a platelet membrane glycoprotein as a falciparum malaria sequestration receptor.

C F Ockenhouse1, N N Tandon, C Magowan, G A Jamieson, J D Chulay.   

Abstract

Infections with the human malaria parasite Plasmodium falciparum are characterized by sequestration of erythrocytes infected with mature forms of the parasite. Sequestration of infected erythrocytes appears to be critical for survival of the parasite and to mediate immunopathological abnormalities in severe malaria. A leukocyte differentiation antigen (CD36) was previously suggested to have a role in sequestration of malaria-infected erythrocytes. CD36 was purified from platelets, where it is known as GPIV, and was shown to be a receptor for binding of infected erythrocytes. Infected erythrocytes adhered to CD36 immobilized on plastic; purified CD36 exhibited saturable, specific binding to infected erythrocytes; and purified CD36 or antibodies to CD36 inhibited and reversed binding of infected erythrocytes to cultured endothelial cells and melanoma cells in vitro. The portion of the CD36 molecule that reverses cytoadherence may be useful therapeutically for rapid reversal of sequestration in cerebral malaria.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2467377     DOI: 10.1126/science.2467377

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  98 in total

1.  Selection for high and low virulence in the malaria parasite Plasmodium chabaudi.

Authors:  M J Mackinnon; A F Read
Journal:  Proc Biol Sci       Date:  1999-04-07       Impact factor: 5.349

2.  The adhesion of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A is mediated by P. falciparum erythrocyte membrane protein 1.

Authors:  J C Reeder; A F Cowman; K M Davern; J G Beeson; J K Thompson; S J Rogerson; G V Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

3.  Commentary on Myers et al.: growing role of the innate immunity receptor CD36 in central nervous system diseases.

Authors:  Lidia Garcia-Bonilla; Laibaik Park; Costantino Iadecola
Journal:  Exp Neurol       Date:  2014-08-23       Impact factor: 5.330

Review 4.  Oxidized phospholipids as endogenous pattern recognition ligands in innate immunity.

Authors:  Stanley L Hazen
Journal:  J Biol Chem       Date:  2008-02-19       Impact factor: 5.157

5.  An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration.

Authors:  G D Turner; H Morrison; M Jones; T M Davis; S Looareesuwan; I D Buley; K C Gatter; C I Newbold; S Pukritayakamee; B Nagachinta
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

6.  Antigenic and functional differences in adhesion of Plasmodium falciparum-infected erythrocytes to human and bovine CD36.

Authors:  C F Ockenhouse; N N Tandon; G A Jamieson; D E Greenwalt
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

7.  T-cell-dependent immunity and thrombocytopenia in rats infected with Plasmodium chabaudi.

Authors:  H Watier; C Verwaerde; I Landau; E Werner; J Fontaine; A Capron; C Auriault
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

8.  Detection of a LFA-1-like epitope on the surface of erythrocytes infected with a strain of Plasmodium falciparum.

Authors:  F Tacchini-Cottier; J N Lou; D J Roberts; A M Garcia; G E Grau
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

9.  Listeria monocytogenes infects human endothelial cells by two distinct mechanisms.

Authors:  D A Drevets; R T Sawyer; T A Potter; P A Campbell
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

10.  The liver as a major site of immunological elimination of murine trypanosome infection, demonstrated with the liver perfusion model.

Authors:  J W Albright; G W Long; J F Albright
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.